@huongtramviet79: Bột trầm hương cao cấp sẽ như thế nào...? #tramhuongkhanhhoa #tramhuong #vongtaytramhuong #tramhuongtunhien #huongtramviet #bottramhuong

Hương Trầm Việt

Open In TikTok:

Region: VN

Tuesday 01 August 2023 14:01:27 GMT

14796

348

22

3

Music

Download

No Watermark .mp4 (47.43MB) No Watermark(HD) .mp4 (36.77MB) Watermark .mp4 (0MB) Music .mp3

Comments

ngocthuy.VTV12 :

bao nhiêu 1 kg

2026-03-20 08:47:52

1

Photo Luan Vo :

Hủ 100 giá bn shop

2023-08-06 14:58:36

1

Ngọc Hà :

Bột nhìn chất quá anh Trường

2023-08-02 06:02:35

1

Quốc Phong :

1 hộp mấy kg

2025-12-30 06:02:21

0

minmin :

Em lấy 5 hủ nha

2023-08-02 15:54:54

1

le961697a5g :

Màu nâu đẹp dầu nhiều

2023-08-02 15:55:33

1

Bảo Bảo :

Mua số lượng được không anh

2023-08-02 11:10:44

0

Chốt đơn đi :

Mua ở đâu anh

2023-08-02 04:47:30

1

kim Thoa bi :

Bột thơm

2023-08-02 04:48:15

1

Minhle :

Mua số lượng được không anh

2023-08-02 06:02:50

1

Dương :

Vạn giã chỗ nào vậy a

2023-08-02 15:55:10

1

Ngân Ngân :

Còn sớ trầm luôn kìa

2023-08-03 02:29:51

1

Tô Hoàng Phúc :

Tuyệt vời quá anh

2023-08-03 18:50:12

1

Photo Luan Vo :

Bn 1 gram shop

2023-08-06 14:56:55

1

Trạm Dừng Chân Audio :

Mua 5 hộp giá ntn shop nhỉ

2023-12-09 06:00:15

1

To see more videos from user @huongtramviet79, please go to the Tikwm homepage.

Other Videos

I love me a pretty book, and these books might just be the prettiest. ❤️🧡💛💚💙💜🩷🖤 I got these for £89 on TikTok shop from @HarperCollinsUK - RRP £173.98!! #ShatterMe #AaronWarner #BookTok #collectorsedition #ad

I love me a pretty book, and these books might just be the prettiest. ❤️🧡💛💚💙💜🩷🖤 I got these for £89 on TikTok shop from @HarperCollinsUK - RRP £173.98!! #ShatterMe #AaronWarner #BookTok #collectorsedition #ad

Eternal love.#eternallove #Love #wholesome #hopecore #fyp

Eternal love.#eternallove #Love #wholesome #hopecore #fyp

Januvia cost Americans around $600 a month for almost twenty years. That run just ended, and the number it landed on says more about our system than the twenty years did. Merck got Januvia approved in October 2006. For the next nineteen years there was no generic in the United States. The cash price ran roughly $500 to $721 for a single thirty day supply. The annual list price in 2023 was $6,346. The same drug cost 66% less in France and 82% less in Canada. Over its life, Januvia has done about $50 billion in global sales. Medicare alone has spent roughly $32.2 billion on it. About 885,000 Part D patients were taking it, close to 1.7% of everybody in the program. The wall held that long because the first patent was never the whole story. Merck also held a patent on the phosphate salt form of the molecule, filed in 2004, issued in 2008, running to March 2027. On top of that it reached 26 separate settlement agreements with generic manufacturers. Analysts figured the extra stretch of exclusivity was worth about $3.5 billion in additional US revenue. None of that is illegal. It is just what the system rewards. Then the wall came down. Watson Labs took the first generic approval on December 30, 2025. Sandoz was first to actually market on January 14, 2026. Apotex and Teva followed on May 28. Once there were several manufacturers instead of one, the price did what prices do when somebody finally has to compete. Here is our shelf price today. Generic sitagliptin 100mg is $51.39 for a thirty day supply. Ninety days is $134. The 50mg and the 25mg cost the same as the 100mg, because the cost to us is basically the same and we are not going to invent a reason to charge you more. Now the part I actually want you to sit with. Januvia was one of the first ten drugs selected for Medicare price negotiation under the Inflation Reduction Act. The federal government, the single most powerful buyer in American healthcare, spent about two years at the table with Merck. The negotiated price took effect this year at $113 per thirty day supply, down 79% from a $527 list price. It was announced as a landmark. Our cash price is $51.39. An independent pharmacy in a strip center beat the negotiated price of the United States government by more than half, with no legislation, no negotiation, and no rebate. Just what the drug costs us plus a fair markup. I am not saying that to brag. I am saying it because it tells you the negotiated price was never close to the floor. It was a discount off a number that was made up in the first place. And a price falling does not mean your price falls. That is the trap. The Association for Accessible Medicines found that only 24% of Medicare Part D plans covered first generic drugs launched in 2024. For commercial plans it was 84%. Even generics from 2021 only reached 42% Part D coverage. The cheaper version existing and your plan letting you have it are two different events. The reason is that the middleman sitting between you and the pharmacy does not make money the way you think. State auditors in Ohio found PBMs kept $224.8 million in a single year through spread pricing, billing the plan one price and paying the pharmacy a lower one. Kentucky found $123.5 million. Michigan found at least $64 million. Maryland, about $72 million a year. That gap is invisible to you because you only ever see your copay. So when a drug like this collapses in price, the savings has to survive a trip through a system that is compensated on the size of the number. Sometimes it makes it to you. Often it does not. This is the whole reason we post real prices publicly. No spread. No formulary games. No rebate we are quietly hoping you never ask about. Cost plus a fair markup, and you see it before you pay.

Januvia cost Americans around $600 a month for almost twenty years. That run just ended, and the number it landed on says more about our system than the twenty years did. Merck got Januvia approved in October 2006. For the next nineteen years there was no generic in the United States. The cash price ran roughly $500 to $721 for a single thirty day supply. The annual list price in 2023 was $6,346. The same drug cost 66% less in France and 82% less in Canada. Over its life, Januvia has done about $50 billion in global sales. Medicare alone has spent roughly $32.2 billion on it. About 885,000 Part D patients were taking it, close to 1.7% of everybody in the program. The wall held that long because the first patent was never the whole story. Merck also held a patent on the phosphate salt form of the molecule, filed in 2004, issued in 2008, running to March 2027. On top of that it reached 26 separate settlement agreements with generic manufacturers. Analysts figured the extra stretch of exclusivity was worth about $3.5 billion in additional US revenue. None of that is illegal. It is just what the system rewards. Then the wall came down. Watson Labs took the first generic approval on December 30, 2025. Sandoz was first to actually market on January 14, 2026. Apotex and Teva followed on May 28. Once there were several manufacturers instead of one, the price did what prices do when somebody finally has to compete. Here is our shelf price today. Generic sitagliptin 100mg is $51.39 for a thirty day supply. Ninety days is $134. The 50mg and the 25mg cost the same as the 100mg, because the cost to us is basically the same and we are not going to invent a reason to charge you more. Now the part I actually want you to sit with. Januvia was one of the first ten drugs selected for Medicare price negotiation under the Inflation Reduction Act. The federal government, the single most powerful buyer in American healthcare, spent about two years at the table with Merck. The negotiated price took effect this year at $113 per thirty day supply, down 79% from a $527 list price. It was announced as a landmark. Our cash price is $51.39. An independent pharmacy in a strip center beat the negotiated price of the United States government by more than half, with no legislation, no negotiation, and no rebate. Just what the drug costs us plus a fair markup. I am not saying that to brag. I am saying it because it tells you the negotiated price was never close to the floor. It was a discount off a number that was made up in the first place. And a price falling does not mean your price falls. That is the trap. The Association for Accessible Medicines found that only 24% of Medicare Part D plans covered first generic drugs launched in 2024. For commercial plans it was 84%. Even generics from 2021 only reached 42% Part D coverage. The cheaper version existing and your plan letting you have it are two different events. The reason is that the middleman sitting between you and the pharmacy does not make money the way you think. State auditors in Ohio found PBMs kept $224.8 million in a single year through spread pricing, billing the plan one price and paying the pharmacy a lower one. Kentucky found $123.5 million. Michigan found at least $64 million. Maryland, about $72 million a year. That gap is invisible to you because you only ever see your copay. So when a drug like this collapses in price, the savings has to survive a trip through a system that is compensated on the size of the number. Sometimes it makes it to you. Often it does not. This is the whole reason we post real prices publicly. No spread. No formulary games. No rebate we are quietly hoping you never ask about. Cost plus a fair markup, and you see it before you pay.

😱 Ви навіть не очікуєте, що станеться…#таролог #картитаро #розкладдлятебе #знакидолі #вірусне

😱 Ви навіть не очікуєте, що станеться…#таролог #картитаро #розкладдлятебе #знакидолі #вірусне

Truth has come, and falsehood has vanished 💯🔥 #god #truth #Jesus

Truth has come, and falsehood has vanished 💯🔥 #god #truth #Jesus

End the safe Zone 🖤 #qr_edits #1M #100klikes #foryoupage @☆° 𝙈𝙊𝙊𝙉 °☆

End the safe Zone 🖤 #qr_edits #1M #100klikes #foryoupage @☆° 𝙈𝙊𝙊𝙉 °☆

About

Robot
API

Legal

Privacy Policy